Navigation Links
Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
Date:8/5/2008

s. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-lookin
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
3. ProMetic provides business update - Over $35 million worth of business secured in January
4. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
5. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
6. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
7. Prometic to present at the American Chemical Society
8. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
9. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
10. Prometic provides information for its Annual and Special Meeting of Shareholders
11. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... that provides innovative genetic analysis solutions, and Mayo ... laboratory services in the United States ... testing patents and applications. "We have great ... patient care, and we welcome the opportunity to partner ...
(Date:7/29/2014)... , July 29, 2014  The Society for ... and updated program for the 9 th ... 2014 in Amelia Island , Florida.  The ... investigators remains unchanged, however, the topics and format ... networking opportunity among all stakeholders with a continued ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, ... with FORMA Therapeutics, Inc., to provide access to ... fragment-based lead discovery platform for novel small molecule ... about the opportunity to work with FORMA Therapeutics ... epigenetics and protein homeostasis. FORMA Therapeutics, decision to ...
(Date:7/29/2014)... Rockville, MD (PRWEB) July 29, 2014 ... (ITI), a vaccine pioneer in the biotechnology industry, ... firm Newport Coast Securities, Inc. to explore financing ... commercializing LAMP-vax technology, a breakthrough vaccine platform with ... immunotherapy market. The company exclusively licensed the well-established ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3
... , ... • chemiluminescence , , ... enzymes exist, their activities having wide-ranging regulatory responses. Many kinases ... as inflammation and cancer, so identifying modulators of kinase and ...
... , , , ... Hancock, Elaine Adie, Molly Price-Jones, Stephen Game & Stuart Swinburne , ... Biosciences UK Limited, Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA England, ... , As high throughput imaging systems, analysis ...
... , ... The Maynard Centre, Cardiff, UK , ... and the development of high-throughput image analysis platforms such as the IN ... we describe the application of two stable cell lines expressing green fluorescent ...
Cached Biology Technology:Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 2Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 3Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 4Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 2Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 3Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 4siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 2siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 3siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 4siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 5siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 6siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005) 7
(Date:7/29/2014)... recover from the debilitating effects of a stroke ... knowledge of neurophysiology as well as effective therapy. ... outcomes has been the primary focus of research ... since he joined the NJIT faculty more than ... is underscored by substantial funding from sources such ...
(Date:7/29/2014)... Aarhus University researchers have developed an easier method ... strengthen the work involved in diagnosing diseases. , ... provides a strong partnership that can be used ... conjugates which tag proteins with DNA ... sensitive detection and visualisation of biological material. The ...
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
Breaking Biology News(10 mins):Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2Counting down to FEBS-EMBO 2014 in Paris, France 2
... The University of Houston department of health and human ... Life (SL) thanks to grants from the UH Faculty ... of the University of Southern California-Annenberg School for Communication. ... ground in Second Life for the benefit of our ...
... The life expectancy for patients with human immunodeficiency ... since the late 1990s thanks to advancements in antiretroviral ... at Birmingham (UAB) and Simon Fraser University in Vancouver, ... nearly 40 percent drop in AIDS deaths among 43,355 ...
... on the brain" must have shunts implanted to drain the ... While shunts do their job well, the rate of ... of reasons, which requires putting the child through another surgery ... potential additional neurological complications and an increased risk of death. ...
Cached Biology News:Second Life a first for UH department of health and human performance 2Anti-HIV therapy boosts life expectancy more than 13 years 2Antimicrobial sutures reduce infections in brain shunt surgery, study finds 2
... includes 1. Scanning of gel(s) 2. ... tryptic in-gel digestion and peptide extraction ... 5. Acquisition of PMF (Peptide Mass ... TOF/TOF) 6. Acquisition of PFF (Peptide ...
... Nucleic acid hybridization Preparation ... mg BSA, 50 mg ficoll ... with 5 ml of water ... for molecular biology Density: 1.00 ...
... ImageXpress 5000A automated cellular imaging and analysis ... system designed specifically for rapid acquisition and ... cell-based screening. ImageXpress is fast. Scanning ... (1280 x 1024 pixels), with two fluorescence ...
... Antibody Capture Kit eliminates ... optimization steps typically required ... This kit enables the ... multiple antigens based on ...
Biology Products: